Monitor the next quarterly filing for any strategic or financial shifts under the new CFO. The appointment of a CFO with capital markets and M&A experience could signal preparation for financing or partnership activity, but no immediate catalyst is indicated.
SCYX drugs
SCYX drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 10 $4.70entry
- T+1 · 2mo ago +2.98%α +2.13% · $4.84
- T+5 · 2mo ago −5.32%α −4.82% · $4.45
- T+20 · 6w ago −10.21%α −12.34% · $4.22
- T+47 · todayOpen
- T+60 · in 17d Pending
Price Chart
How similar events traded
Executive Summary
SCYNEXIS announced the retirement of CFO Ivor Macleod effective September 9, 2026, and the immediate appointment of Sanjay Subramanian as new CFO. The transition is orderly with a one-month overlap, and Mr. Subramanian brings relevant biopharma finance experience including a prior acquisition exit. This is a routine executive change with no new financial disclosures or strategic updates.
Key Facts
- CFO Ivor Macleod retired effective September 9, 2026 and will remain through October 9, 2026 for transition support.
- Sanjay Subramanian appointed CFO effective September 9, 2026; he previously served as CFO at Inozyme Pharma and Ocugen.
- New CFO receives a $500,000 base salary, $20,000 sign-on bonus, up to 40% annual bonus, and a stock option for 100,000 shares at $4.91 (closing price on grant date) vesting over four years.
- Severance provides 9 months base salary (18 months if terminated within 12 months after a change of control) plus accelerated equity vesting.
Financial Impact
No material financial impact from the executive change. New CFO compensation is within normal range for a clinical-stage biotech of this market cap.
Risk Factors
- No immediate risks identified from this routine executive transition.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001178253-26-000031 |
| Document: scyx-ex99_1.htm | 0001178253-26-000031 |
| Document: 0001178253-26-000031-index-headers.html | 0001178253-26-000031 |
| Document: 0001178253-26-000031-index.html | 0001178253-26-000031 |
| Document: 0001178253-26-000031.txt | 0001178253-26-000031 |
Track record
15 reports on SCYX
5 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +33.49% at T+20 after the May 11, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Bearish 5/10 Entry $2.91 Now $2.91 −0.00% settles Nov 24
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $2.91 Now $2.91 +0.00% settles Nov 24
- Nov 5, 202611d ago S-3 Neutral 3/10 Entry $3.30 to $3.33 Now $2.91 −11.82% ▲ +0.91% −2.38% vs SPY
- Nov 5, 202611d ago Press Release Neutral 4/10 Entry $3.30 to $3.33 Now $2.91 −11.82% ▲ +0.91% −2.38% vs SPY
- Oct 22, 202625d ago Press Release Bullish 7/10 Entry $3.81 to $3.86 Now $2.91 −23.62% ▲ +1.31% +0.61% vs SPY
- Oct 6, 20265w ago Press Release Neutral 4/10 Entry $4.84 to $3.99 Now $2.91 −39.88% ▼ −17.56% −17.42% vs SPY
- Sep 28, 20267w ago Press Release Bullish 6/10 Entry $4.62 to $5.03 Now $2.91 −37.01% ▲ +8.87% +7.67% vs SPY
- Sep 22, 20267w ago 8-K Neutral 2/10 Entry $4.86 to $4.66 Now $2.91 −40.12% ▼ −4.12% −2.93% vs SPY
- Sep 10, 20269w ago 8-K Neutral 2/10 Viewing Entry $4.70 to $4.45 Now $2.91 −38.09% ▼ −5.32% −4.82% vs SPY
- Jun 26, 202620w ago 8-K Neutral 3/10 Entry $3.87 to $4.73 Now $2.91 −24.81% ▲ +22.22% +20.83% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers